Radiation Therapy in Burkitt Lymphoma

  • Michael Oertel
  • Oliver MickeEmail author
  • Hans Theodor Eich
Living reference work entry


Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma revealing one of the highest proliferation rates in malignancies. Its frequent extranodal involvement and possible generalization to an acute leukemia challenge effective treatment which normally consists of a poly-agent chemotherapy. The following chapter sheds light on epidemiology, tumor biology, treatment options and prognosis of this lymphoma which has evolved from an enigmatic syndrome to a curable disease.


Lymphoma Burkitt Agressive Stem cell Transplantation CNS 


  1. Aramsri B, Piyaratn P, Kambhu P, Thitathan S. Burkitt’s tumour in a Thai patient. Int J Cancer. 1967;2:586–7.CrossRefPubMedGoogle Scholar
  2. Blum KA. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20. Scholar
  3. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218–23. Scholar
  4. Collins CD, Pullan JM, Tighe JR, Vanier TM. A case of Burkitt’s lymphoma in England. Int J Cancer. 1967;2:590–1.CrossRefPubMedGoogle Scholar
  5. Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121:4861–6. Scholar
  6. Delemarre JF, Hollander CF, Frenkel M, de Leeuw-Israel FR. A case of a so-called “Burkitt tumor” in a Dutch boy. Int J Cancer. 1967;2:594–5.CrossRefPubMedGoogle Scholar
  7. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25. Scholar
  8. Ersbøll J, Schultz HB, Thomsen BL, et al. Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35:487–96.CrossRefPubMedGoogle Scholar
  9. Haddy TB, Adde MA, Magrath IT. CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol. 1991;9:1973–82. Scholar
  10. Hall RK, Cussen LJ. Burkitt’s tumour – an Australian case. Int J Cancer. 1967;2:599–602.CrossRefPubMedGoogle Scholar
  11. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedPubMedCentralGoogle Scholar
  12. Hoelzer D, Ludwig W, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495.PubMedGoogle Scholar
  13. Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l’Enfant study. Haematologica. 2015;100:810–7. Scholar
  14. Kim H, Park ES, Lee SH, et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat Off J Korean Cancer Assoc. 2014;46:358–65. Scholar
  15. Lacasce A, Howard O, Li S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–7. Scholar
  16. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:4014–22. Scholar
  17. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin’s lymphoma: the risk factors. Hematol Oncol. 1990;8:141–5.CrossRefPubMedGoogle Scholar
  18. Magrath IT, Lwanga S, Carswell W, Harrison N. Surgical reduction of tumour bulk in management of abdominal Burkitt’s lymphoma. Br Med J. 1974;2:308–12.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925–34. Scholar
  20. Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19:173–9. Scholar
  21. Martens C, Hodgson DC, Wells WA, et al. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin’s lymphoma. Int J Radiat Oncol. 2006;64:1183–7. Scholar
  22. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol Off J Eur Soc Med Oncol. 2002;13:1264–74.CrossRefGoogle Scholar
  23. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–60. Scholar
  24. Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet Lond Engl. 2012;379:1234–44. Scholar
  25. Mukhtar F, Boffetta P, Risch HA, et al. Survival predictors of Burkitt’s lymphoma in children, adults and elderly in the United States during 2000-2013. Int J Cancer. 2017;140:1494–502. Scholar
  26. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin’s lymphoma. Cancer. 1980;45:630–7.CrossRefPubMedGoogle Scholar
  27. Norin T. Radiation therapy in Burkitt’s lymphoma: long term results. Acta Radiol Ther Phys Biol. 1977a;16:289–94. Scholar
  28. Norin T. Radiation therapy in Burkitt’s lymphoma of the central nervous system: primary results. Acta Radiol Ther Phys Biol. 1977b;16:73–80. Scholar
  29. Norin T, Onyango J. Radiotherapy in Burkitt’s lymphoma conventional or superfractionated regime – early results. Int J Radiat Oncol. 1977;2:399–406. Scholar
  30. Pilecki B, Kopiec P, Zajusz A, et al. Hyperfractionated radiotherapy for Burkitt-type lymphoma. Radiobiological aspects. Neoplasma. 1991;38:609–15.PubMedGoogle Scholar
  31. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–11. Scholar
  32. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B study 9251. Cancer. 2004;100:1438–48. Scholar
  33. Shamberger RC, Weinstein HJ. The role of surgery in abdominal Burkitt’s lymphoma. J Pediatr Surg. 1992;27:236–40. Scholar
  34. Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma: SHORT et al. Am J Hematol. 2017;92:E114–7. Scholar
  35. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995;85:664–74.PubMedGoogle Scholar
  36. Stein JE, Schwenn MR, Jacir NN, Harris BH. Surgical restraint in Burkitt’s lymphoma in children. J Pediatr Surg. 1991;26:1273–5. Scholar
  37. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–59. Scholar
  38. Thomas DA, Cortes J, O’Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:2461–70. Scholar
  39. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80. Scholar
  40. World Health Organization (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition. International Agency for Research on Cancer, Lyon.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael Oertel
    • 1
  • Oliver Micke
    • 2
    Email author
  • Hans Theodor Eich
    • 1
  1. 1.Department of Radiation OncologyUniversity of MuensterMuensterGermany
  2. 2.Department of Radiotherapy and Radiation OncologyFranziskus HospitalBielefeldGermany

Personalised recommendations